Personalis, Inc. to Provide Comprehensive Tumor Immunogenomic Profiling to the New Mexico Cancer Care Alliance for Clinical S...
07 8월 2019 - 9:00PM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for cancer, today announced that The University of New Mexico (UNM)
Comprehensive Cancer Center and the New Mexico Alliance for Cancer
Care will utilize Personalis’ cancer immunogenomics platform,
ImmunoID NeXT™, for the investigation of biomarkers of response to
a novel treatment paradigm in women with ovarian cancer. The basis
of this trial, which evaluates the combination of Olaparib and
Tremelimumab in women with recurrent BRCA-deficient ovarian
cancers, is based on the work of Sarah Adams, MD, that indicated
that immune priming with targeted cytotoxic therapy using a
PARP-inhibitor can sensitize ovarian tumors to immune therapy and
optimize patient survival. The clinical trial is being conducted at
several ORIEN centers across the United States. For more
information please visit clinicaltrials.gov identifier
NCT02571725.
“We are delighted to collaborate with Personalis on this study,”
said the principal investigator of the study, Dr. Adams, Associate
Professor, Division of Gynecologic Oncology at the UNM
Comprehensive Cancer Center. “Comprehensive immuno-profiling will
inform on biomarkers of response for this experimental treatment in
women with BRCA1 or BRCA2 germline mutated ovarian cancers, for
which there aren’t standard curative measures.”
Personalis ImmunoID NeXT™ Platform provides a comprehensive
interrogation and analysis of ~20,000 genes in both DNA and RNA.
The platform is an end-to-end solution for immuno- and precision
oncology biomarker discovery applications, simultaneously enabling
the analysis of: tumor escape mechanisms (including HLA typing and
somatic mutation detection), immune repertoire profiles, neoantigen
load, tumor mutational burden (TMB), microsatellite instability
(MSI), oncoviruses, and immune checkpoint gene expression.
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company
transforming the development of next-generation therapies by
providing more comprehensive molecular data about each patient’s
cancer and immune response. The company’s NeXT™ Platform is
designed to adapt to the complex and evolving understanding of
cancer, providing its biopharmaceutical customers with information
on all of the approximately 20,000 human genes, together with the
immune system, from a single tissue sample. The Personalis Clinical
Laboratory is GxP aligned as well as CLIA’88-certified and
CAP-accredited. For more information, please visit
www.personalis.com and follow Personalis on Twitter
(@PersonalisInc).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190807005181/en/
Investor Relations Contact for Personalis: Caroline
Corner investors@personalis.com www.westwicke.com 415-202-5678
Media Contact for Personalis: Jennifer Havlek
pr@personalis.com www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024